Rossari Biotech Ltd
Rossari Biotech was started in 2003.
They are among the largest manufacturers
of textile specialty chemicals in India.[1]
- Market Cap ₹ 2,723 Cr.
- Current Price ₹ 492
- High / Low ₹ 729 / 373
- Stock P/E 18.1
- Book Value ₹ 241
- Dividend Yield 0.10 %
- ROCE 13.3 %
- ROE 10.8 %
- Face Value ₹ 2.00
Pros
- Company's working capital requirements have reduced from 62.4 days to 48.6 days
Cons
- Company has a low return on equity of 12.0% over last 3 years.
- Dividend payout has been low at 2.00% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE Commodities BSE 1000
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 2,080 | 2,396 | 2,550 | |
| 438 | 495 | 586 | 1,299 | 1,433 | 1,581 | 1,815 | 2,110 | 2,251 | |
| Operating Profit | 78 | 105 | 124 | 184 | 223 | 250 | 265 | 286 | 299 |
| OPM % | 15% | 17% | 17% | 12% | 13% | 14% | 13% | 12% | 12% |
| 1 | 4 | 9 | 13 | 6 | 8 | 5 | 24 | 26 | |
| Interest | 3 | 4 | 3 | 13 | 22 | 19 | 18 | 29 | 34 |
| Depreciation | 12 | 17 | 23 | 48 | 63 | 60 | 67 | 79 | 87 |
| Profit before tax | 63 | 88 | 107 | 136 | 144 | 178 | 185 | 203 | 204 |
| Tax % | 28% | 26% | 25% | 28% | 26% | 26% | 26% | 26% | |
| 46 | 65 | 80 | 98 | 107 | 131 | 136 | 149 | 151 | |
| EPS in Rs | 103.82 | 12.86 | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 | 26.94 | 27.22 |
| Dividend Payout % | 0% | 4% | 3% | 3% | 3% | 2% | 2% | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 13% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 8% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -17% |
| 3 Years: | -18% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 12% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 10 | 10 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 119 | 277 | 398 | 794 | 904 | 1,037 | 1,174 | 1,322 |
| 8 | 67 | 0 | 8 | 74 | 119 | 218 | 436 | |
| 118 | 118 | 152 | 442 | 375 | 401 | 482 | 505 | |
| Total Liabilities | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,274 |
| 74 | 94 | 181 | 607 | 585 | 578 | 598 | 784 | |
| CWIP | 3 | 22 | 0 | 1 | 16 | 47 | 140 | 173 |
| Investments | 0 | 18 | 0 | 36 | 51 | 63 | 84 | 62 |
| 173 | 338 | 379 | 611 | 712 | 880 | 1,063 | 1,254 | |
| Total Assets | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,274 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 71 | 57 | 48 | 29 | 152 | 43 | 137 | 65 | |
| -37 | -190 | -37 | -299 | -181 | -103 | -183 | -220 | |
| -29 | 157 | -25 | 292 | 61 | 16 | 65 | 186 | |
| Net Cash Flow | 5 | 23 | -14 | 22 | 32 | -44 | 19 | 31 |
| Free Cash Flow | 27 | -19 | -8 | -7 | 120 | -83 | -21 | -175 |
| CFO/OP | 118% | 74% | 64% | 43% | 89% | 39% | 74% | 47% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 57 | 74 | 75 | 78 | 85 | 83 | 85 |
| Inventory Days | 59 | 57 | 75 | 63 | 59 | 80 | 90 | 88 |
| Days Payable | 114 | 95 | 104 | 61 | 56 | 62 | 73 | 71 |
| Cash Conversion Cycle | 6 | 19 | 46 | 76 | 80 | 103 | 101 | 103 |
| Working Capital Days | 23 | 22 | 60 | 62 | 49 | 70 | 69 | 49 |
| ROCE % | 38% | 29% | 24% | 18% | 18% | 16% | 13% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Installed Capacity MTPA |
|
|||||||||
| Number of Customers customers |
||||||||||
| Number of Products products |
||||||||||
| Number of Countries Exported To countries |
||||||||||
| Export Revenue Rs. crore |
||||||||||
| AHN Segment Revenue Rs. crore |
||||||||||
| HPPC Segment Revenue Rs. crore |
||||||||||
| TSC Segment Revenue Rs. crore |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
2d - Rossari Biotech 17th AGM held July 20, 2026; all 8 resolutions passed, including Re.0.50 dividend.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
2d - Rossari Biotech’s 17th AGM on July 20, 2026 passed all 8 resolutions, including Re.0.50 dividend.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
2d - Rossari Biotech shared Q1 FY27 earnings call audio recording on July 20, 2026.
-
Update On Grant Of Options.
2d - Rossari Biotech corrected ESOP grant to 5,000 options, replacing 4,000, from July 18, 2026 board meeting.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
19 Jul - Rossari Biotech reported Q1 FY27 revenue of Rs. 697.2 crore, EBITDA of Rs. 80.6 crore, PAT of Rs. 35.1 crore; opened Thailand facility.
Annual reports
Concalls
-
Jul 2026TranscriptPPT REC
-
May 2026Transcript PPT REC
-
Jan 2026Transcript PPT REC
-
Oct 2025Transcript PPT REC
-
Jul 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Oct 2021TranscriptAI SummaryPPT
-
Aug 2021Transcript PPT
-
Jul 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Oct 2020Transcript PPT
-
Aug 2020Transcript PPT
Product Segments:[1]
The company is one of India’s leading specialty chemicals manufacturer offering 4,280+ products across 3 verticals: